Edward Fox

8.8k total citations · 3 hit papers
156 papers, 6.0k citations indexed

About

Edward Fox is a scholar working on Pathology and Forensic Medicine, Rheumatology and Surgery. According to data from OpenAlex, Edward Fox has authored 156 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Pathology and Forensic Medicine, 42 papers in Rheumatology and 31 papers in Surgery. Recurrent topics in Edward Fox's work include Multiple Sclerosis Research Studies (76 papers), Peripheral Neuropathies and Disorders (24 papers) and Immunotherapy and Immune Responses (19 papers). Edward Fox is often cited by papers focused on Multiple Sclerosis Research Studies (76 papers), Peripheral Neuropathies and Disorders (24 papers) and Immunotherapy and Immune Responses (19 papers). Edward Fox collaborates with scholars based in United States, United Kingdom and Canada. Edward Fox's co-authors include David Margolin, Alasdair Coles, Krzysztof Selmaj, D. A. S. Compston, Stephen Lake, Douglas L. Arnold, Eva Havrdová, Jeffrey Cohen, Michael Panzara and Howard L. Weiner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Edward Fox

150 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

2012 884 citations Alasdair Coles, Cary Twyman et al. profile →
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

2012 883 citations Jeffrey Cohen, Alasdair Coles et al. profile →
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

2020 317 citations Edward Fox et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward Fox United States	35	3.6k	1.5k	1.5k	1.3k	1.2k	156	6.0k
Riccardo Saccardi Italy	46	2.3k 0.6×	492 0.3×	1.5k 1.0×	605 0.5×	1.2k 1.0×	181	6.1k
Michael Møller Denmark	34	1.6k 0.4×	549 0.4×	1.3k 0.8×	670 0.5×	945 0.8×	161	4.2k
Thomas F.E. Barth Germany	46	2.4k 0.7×	414 0.3×	2.0k 1.3×	455 0.3×	1.7k 1.4×	236	7.0k
Bahram Bodaghi France	51	846 0.2×	1.1k 0.8×	601 0.4×	1.9k 1.4×	836 0.7×	363	9.1k
Thierry Jo Molina France	46	3.6k 1.0×	1.2k 0.8×	3.4k 2.2×	257 0.2×	2.8k 2.4×	252	9.2k
Peter Chang United States	34	1.4k 0.4×	519 0.3×	781 0.5×	731 0.5×	430 0.4×	151	4.5k
Marta Mosca Italy	46	1.6k 0.4×	445 0.3×	492 0.3×	4.4k 3.3×	2.5k 2.1×	311	7.7k
Jacques‐Eric Gottenberg France	46	1.0k 0.3×	321 0.2×	732 0.5×	2.7k 2.0×	1.7k 1.4×	163	7.1k
Dominique Bron Belgium	56	3.4k 0.9×	942 0.6×	3.8k 2.5×	284 0.2×	2.2k 1.9×	304	11.7k
Marc E. Horowitz United States	41	698 0.2×	1.3k 0.9×	1.2k 0.8×	433 0.3×	648 0.5×	98	5.9k

Countries citing papers authored by Edward Fox

Since Specialization

Citations

This map shows the geographic impact of Edward Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Fox more than expected).

Fields of papers citing papers by Edward Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Fox. The network helps show where Edward Fox may publish in the future.

Co-authorship network of co-authors of Edward Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Fox. A scholar is included among the top collaborators of Edward Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Fox. Edward Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benedict, Claude R., et al.. (2025). Rate of Osteoporosis Evaluation and Treatment Following Kyphoplasty in Patients With Vertebral Compression Fractures: A Retrospective Study and Review of the Literature. Geriatric Orthopaedic Surgery & Rehabilitation. 16. 2554040687–2554040687.

Fox, Edward, et al.. (2024). Utility of a bone health clinic in bridging the osteoporosis care gap: Prescribing habit review at an academic institution. PLoS ONE. 19(7). e0307029–e0307029.

Fox, Edward, Lawrence Steinman, Hans‐Peter Hartung, et al.. (2022). Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010). Neurology. 98(18_supplement). 1 indexed citations

Cree, Bruce, Edward Fox, Hans‐Peter Hartung, et al.. (2022). Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009). Neurology. 98(18_supplement). 1 indexed citations

Hauser, Stephen L., Edward Fox, Wendy Su, et al.. (2022). Long-term Efficacy of Ofatumumab in Patients With Relapsing Multiple Sclerosis (P5-4.004). Neurology. 98(18_supplement). 3 indexed citations

Lazarus, Michelle D., et al.. (2021). Resident Training and the Assessment of Orthopaedic Surgical Skills. JBJS Open Access. 6(4). 8 indexed citations

Zaorsky, Nicholas G., Menglu Liang, Christine Lin, et al.. (2021). Survival after palliative radiation therapy for cancer: The METSSS model. Radiotherapy and Oncology. 158. 104–111. 14 indexed citations

Fox, Edward, et al.. (2019). Acute Postoperative Pain Management After Major Limb Amputation in a Pediatric Patient: A Case Report. Journal of PeriAnesthesia Nursing. 34(4). 801–809. 3 indexed citations

Fox, Edward, Fred Lublin, Jerry S. Wolinsky, et al.. (2018). Analysis of lymphocyte counts and infection rates with fingolimod in patients with primary progressive multiple sclerosis over the INFORMS trial (P1.387). Neurology. 90(15_supplement). 1 indexed citations

10.

Fox, Edward, David Brassat, Raed Alroughani, et al.. (2017). Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) (S24.006). Neurology. 88(16_supplement). 2 indexed citations

11.

Coles, Alasdair, Alexey Boyко, J. A. Cohen, et al.. (2016). Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. Multiple Sclerosis Journal. 22. 75–76. 7 indexed citations

12.

Schippling, Sven, Jeffrey A. Cohen, Alasdair Coles, et al.. (2016). Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001). Neurology. 86(16_supplement). 2 indexed citations

13.

Barkhof, Frederik, Jeffrey A. Cohen, Alasdair Coles, et al.. (2016). RRMS Patients Switching from SC IFNB-1a to Alemtuzumab in the CARE-MS I and II Extension Study Have a Reduced Rate of Brain Volume Loss (P6.183). Neurology. 86(16_supplement). 2 indexed citations

14.

Havrdová, Eva, Gavin Giovannoni, Douglas L. Arnold, et al.. (2015). Durable Effect of Alemtuzumab on Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7.276). Neurology. 84(14_supplement). 3 indexed citations

15.

Singer, B., Edward Fox, Stephen Krieger, et al.. (2015). Durable Efficacy of Alemtuzumab in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P7.269). Neurology. 84(14_supplement). 1 indexed citations

16.

Hartung, Hans, Timothy Vollmer, Douglas L. Arnold, et al.. (2013). Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093). Neurology. 80(7_supplement). 2 indexed citations

17.

Giovannoni, Gavin, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120). Neurology. 80(7_supplement). 1 indexed citations

18.

Wray, Sibyl, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172). Neurology. 80(7_supplement). 1 indexed citations

19.

LaGanke, Christopher, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174). Neurology. 80(7_supplement). 3 indexed citations

20.

Crawford, Eileen A., Joseph J. King, Edward Fox, & Christian M. Ogilvie. (2009). Symptomatic Fat Necrosis and Lipoatrophy of the Posterior Pelvis Following Trauma. Orthopedics. 32(6). 444–448. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact